Trials / Completed
CompletedNCT01867242
Methods Project 4: Clinical Trial
PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT Part of "MODELS FOR TOBACCO PRODUCT EVALUATION
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Cigarette smokers who are eligible will enter a Camel Snus sampling phase. Smokers interested in continuing with the study after the sampling phase will undergo a 2 week baseline assessment phase and will then be randomized to one of the three experimental conditions for 8 weeks. Tobacco use patterns, subjective responses to product, and nicotine and toxicant exposure will be assessed.
Detailed description
Baseline smoking period: Subjects will be required to attend 2 baseline clinic visits where baseline assessments will be captured including a record of their cigarette or other tobacco intake on a daily basis using an interactive voice response system (IVR). Experimental Period: After the baseline assessment, subjects will be randomized to one of five experimental conditions: 1) smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus to use as they will for 8 more weeks; 2) complete substitution (i.e., no smoking) and use snus instead ; 3) partial substitution - use of both snus and cigarettes as you like. Snus, but not cigarettes, will be provided to subjects at the clinic visits. Subjects will attend clinic visits over the next 8 weeks where tobacco use patterns and biomarker data will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Cigarettes | Smoke their usual brand of cigarettes and follow their normal patterns of use. |
| OTHER | Snus | Winterchill or Robust flavors |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2017-02-01
- Completion
- 2018-05-01
- First posted
- 2013-06-03
- Last updated
- 2023-05-03
- Results posted
- 2023-04-25
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01867242. Inclusion in this directory is not an endorsement.